Skip to main content
ROHTO PHARMACEUTICAL CO.,LTD. logo

ROHTO PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4527 ISIN · JP3982400008 LEI · 353800Q1CW5OS81OUM12 T Manufacturing
Open in API
Filings indexed 70 across all filing types
Latest filing 2026-05-11 Transaction in Own Shar…
Country JP Japan
Listing T 4527

About ROHTO PHARMACEUTICAL CO.,LTD.

https://www.rohto.co.jp/global/

Rohto Pharmaceutical Co., Ltd. is a multinational company that manufactures and markets a wide range of health and beauty care products. The company's core business areas are over-the-counter (OTC) pharmaceuticals and skincare. It is a recognized leader in the eye care market, particularly known for its extensive line of eye drops. The product portfolio also includes skincare, oral medications, and functional foods. Rohto Pharmaceutical focuses on research and development to create innovative products and services that support the physical and mental well-being of consumers worldwide, aiming to contribute to the future potential of society through health.

Recent filings

Filing Released Lang Actions
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 95% confidence The document is titled “自己株券買付状況報告書” under the Financial Instruments and Exchange Act, detailing the company’s own share repurchase status (dates, amounts, totals). This matches the definition of “Transaction in Own Shares” (share buyback/issuance report).
2026-05-11 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 96% confidence The document is titled “自己株券買付状況報告書” and cites Financial Instruments and Exchange Act Article 24-6, describing details of share repurchase (number of shares, acquisition period, progress, and holdings). This is a regulatory report on the company’s own share transactions (share buyback). According to the classification rules, this falls under Transaction in Own Shares (Code: POS).
2026-04-20 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Kakuninsho' (Confirmation Letter) filed under the Financial Instruments and Exchange Act in Japan. It serves as an officer certification regarding the accuracy of the company's semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like an interim/semi-annual report. H1 2025
2025-11-14 Japanese
半期報告書－第90期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Rohto Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau in Japan. It covers the interim accounting period from April 1, 2025, to September 30, 2025. This document contains comprehensive financial statements, management analysis, and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 90
2025-11-14 Japanese
訂正確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (775 characters) and contains a header section indicating it is a "確認書" (Confirmation Document) submitted to the Kanto Local Finance Bureau Director based on Article 24-4-2, Paragraph 4 of the Financial Instruments and Exchange Act. The main body explicitly states that the Representative Director and CFO confirm that the contents of the 'Correction Report for the Securities Report' (有価証券報告書の訂正報告書) for the 89th fiscal period are appropriate. Since this document is a confirmation *about* a previously filed report (a correction report for a Securities Report, which is typically a 10-K equivalent in Japan, or a comprehensive annual filing), and it is very brief, it functions as an official regulatory confirmation filing rather than the full report itself. Given the options, this type of confirmation/attestation document related to regulatory compliance, which is not a standard report (10-K, IR, ER), best fits the general 'Regulatory Filings' category (RNS) or potentially a specific confirmation type if one existed. However, since it is a formal submission confirming the accuracy of a major filing, and it is not an announcement of a report release (RPA), RNS is the most appropriate fallback for a specific regulatory confirmation document that doesn't match other categories. FY 2025
2025-07-11 Japanese
訂正有価証券報告書－第89期(2024/04/01－2025/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yukashoken Hokokusho' (Annual Securities Report), which is the Japanese equivalent of a 10-K. The header explicitly identifies it as an 'Annual Securities Report' (有価証券報告書) for the 89th fiscal year (2024-04-01 to 2025-03-31), filed under the Financial Instruments and Exchange Act. It contains comprehensive financial data and XBRL tags, confirming it is the full annual report rather than an announcement. FY 2025
2025-07-11 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.